Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siCPT1A is a **small interfering RNA (siRNA)** designed to specifically silence the expression of the *carnitine palmitoyltransferase 1A (CPT1A)* gene. CPT1A is an enzyme critical for mitochondrial fatty acid oxidation, highly expressed in metabolically active tissues like liver and in certain cancer cell contexts. siCPT1A functions by promoting the degradation of CPT1A mRNA, thus reducing protein production. Research using siCPT1A has shown that **inhibiting CPT1A sensitizes cancer cells to chemotherapy, suppresses cancer stem cell stemness, and reduces the activation of hepatic stellate cells implicated in fibrosis**. These findings suggest that siCPT1A, as a molecular research tool or experimental therapeutic, has potential utility in diseases involving CPT1A overactivity—particularly in oncology (ovarian cancer, liver cancer) and fibrotic disorders[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siCPT1A.